152 related articles for article (PubMed ID: 32504368)
21. Effect on Germline Mutation Rate in a High-Risk Chinese Breast Cancer Cohort after Compliance with The National Comprehensive Cancer Network (NCCN) 2023 v.1 Testing Criteria.
Kwong A; Ho CYS; Luk WP; Fung LH; Au CH; Ma ESK
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174101
[TBL] [Abstract][Full Text] [Related]
22. Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis.
Sandoval RL; Leite ACR; Barbalho DM; Assad DX; Barroso R; Polidorio N; Dos Anjos CH; de Miranda AD; Ferreira ACSM; Fernandes GDS; Achatz MI
PLoS One; 2021; 16(2):e0247363. PubMed ID: 33606809
[TBL] [Abstract][Full Text] [Related]
23. Novel mutations in actionable breast cancer genes by targeted sequencing in an ethnically homogenous cohort.
Akter H; Sultana N; Martuza N; Siddiqua A; Dity NJ; Rahaman MA; Samara B; Sayeed A; Basiruzzaman M; Rahman MM; Rashidul Hoq M; Amin MR; Baqui MA; Woodbury-Smith M; Uddin KMF; Islam SS; Awwal R; Berdiev BK; Uddin M
BMC Med Genet; 2019 Sep; 20(1):150. PubMed ID: 31477031
[TBL] [Abstract][Full Text] [Related]
24. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
Hoyer J; Vasileiou G; Uebe S; Wunderle M; Kraus C; Fasching PA; Thiel CT; Hartmann A; Beckmann MW; Lux MP; Reis A
BMC Cancer; 2018 Sep; 18(1):926. PubMed ID: 30257646
[TBL] [Abstract][Full Text] [Related]
25. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
[TBL] [Abstract][Full Text] [Related]
26. Early-onset malignant phyllodes breast tumor in a patient with germline pathogenic variants in NF1 and BRCA1 genes.
Gensini F; Sestini R; De Luca A; Pinna V; Daniele P; Orzalesi L; Petrella MC; Porfirio B; Papi L
Fam Cancer; 2021 Jul; 20(3):195-199. PubMed ID: 33210232
[TBL] [Abstract][Full Text] [Related]
27. Using next-generation sequencing (NGS) platform to diagnose pathogenic germline BRCA1/2 mutations from archival tumor specimens.
Ong PY; Poon SL; Tan KT; Putti TC; Ow SGW; Chen SJ; Chen CH; Lee SC
Gynecol Oncol; 2019 Nov; 155(2):275-279. PubMed ID: 31481248
[TBL] [Abstract][Full Text] [Related]
28. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of germline TP53 mutations in HER2+ breast cancer patients.
Rath MG; Masciari S; Gelman R; Miron A; Miron P; Foley K; Richardson AL; Krop IE; Verselis SJ; Dillon DA; Garber JE
Breast Cancer Res Treat; 2013 May; 139(1):193-8. PubMed ID: 23580068
[TBL] [Abstract][Full Text] [Related]
30. BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.
Monnerat C; Chompret A; Kannengiesser C; Avril MF; Janin N; Spatz A; Guinebretière JM; Marian C; Barrois M; Boitier F; Lenoir GM; Bressac-de Paillerets B
Fam Cancer; 2007; 6(4):453-61. PubMed ID: 17624602
[TBL] [Abstract][Full Text] [Related]
31. Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.
Theobald KA; Susswein LR; Marshall ML; Roberts ME; Mester JL; Speyer D; Williams RNW; Knapke SC; Solomon SR; Murphy PD; Klein RT; Hruska KS; Solomon BD
Ann Surg Oncol; 2018 Nov; 25(12):3556-3562. PubMed ID: 30167906
[TBL] [Abstract][Full Text] [Related]
32. Women with breast and uterine cancer are more likely to harbor germline mutations than women with breast or uterine cancer alone: A case for expanded gene testing.
Fulk K; Milam MR; Li S; Yussuf A; Black MH; Chao EC; LaDuca H; Stany MP
Gynecol Oncol; 2019 Mar; 152(3):612-617. PubMed ID: 30612783
[TBL] [Abstract][Full Text] [Related]
33. Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study.
Mouchawar J; Korch C; Byers T; Pitts TM; Li E; McCredie MR; Giles GG; Hopper JL; Southey MC
Cancer Res; 2010 Jun; 70(12):4795-800. PubMed ID: 20501846
[TBL] [Abstract][Full Text] [Related]
34. Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes.
Wang J; Li W; Shi Y; Huang Y; Sun T; Tang L; Lu Q; Lei Q; Liao N; Jin F; Li H; Huang T; Qian J; Pang D; Wang S; Fan P; Wu X; Lin Y; Qin H; Xu B
Cancer Med; 2019 May; 8(5):2074-2084. PubMed ID: 30982232
[TBL] [Abstract][Full Text] [Related]
35. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
Tung N; Battelli C; Allen B; Kaldate R; Bhatnagar S; Bowles K; Timms K; Garber JE; Herold C; Ellisen L; Krejdovsky J; DeLeonardis K; Sedgwick K; Soltis K; Roa B; Wenstrup RJ; Hartman AR
Cancer; 2015 Jan; 121(1):25-33. PubMed ID: 25186627
[TBL] [Abstract][Full Text] [Related]
36. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
37. Detection of Germline Mutations in Breast Cancer Patients with Clinical Features of Hereditary Cancer Syndrome Using a Multi-Gene Panel Test.
Shin HC; Lee HB; Yoo TK; Lee ES; Kim RN; Park B; Yoon KA; Park C; Lee ES; Moon HG; Noh DY; Kong SY; Han W
Cancer Res Treat; 2020 Jul; 52(3):697-713. PubMed ID: 32019277
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer.
Zhang J; Sun J; Chen J; Yao L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Breast Cancer Res Treat; 2016 Aug; 158(3):455-62. PubMed ID: 27393621
[TBL] [Abstract][Full Text] [Related]
39. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL
J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778
[TBL] [Abstract][Full Text] [Related]
40. Breast Radiation Therapy-Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing.
Chapman BV; Liu D; Shen Y; Olamigoke OO; Lakomy DS; Barrera AMG; Stecklein SR; Sawakuchi GO; Bright SJ; Bedrosian I; Litton JK; Smith BD; Woodward WA; Perkins GH; Hoffman KE; Stauder MC; Strom EA; Arun BK; Shaitelman SF
Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):437-444. PubMed ID: 34582940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
